Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer By The Numbers: 800 R&D Job Cuts But At Least Two Dozen Phase III Projects By Year End

This article was originally published in The Pink Sheet Daily

Executive Summary

Research chief Mackay says Pfizer's research portfolio has been extensively reviewed by both internal and outside experts

You may also be interested in...



Pfizer Selects Sites for its Post-Merger Global R&D Network

Newly merged company will cut R&D staff by 15 percent, though timing is unclear.

Pfizer Selects Sites for its Post-Merger Global R&D Network

Newly merged company will cut R&D staff by 15 percent, though timing is unclear.

Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?

A mega merger combining Pfizer and Wyeth would create a behemoth with combined sales of over $70 billion, build Pfizer's experience base in biotech, give Pfizer the substantial vaccine business it has been searching for and create billions in cost savings opportunities

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel